Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Minireview: Gut peptides regulating satiety.

Maralyn R Druce1, Caroline J Small, Stephen R Bloom

  • 1Department of Metabolic Medicine, Division of Investigative Science, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 ONN, United Kingdom.

Endocrinology
|March 27, 2004
PubMed
Summary

Obesity is a major global health crisis. Replacing low levels of peptide YY (PYY) in obese individuals may offer an effective therapy to reduce appetite and combat obesity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Familial medullary thyroid carcinoma secondary to an <i>SLC30A9</i> intragenic deletion and translation reinitiation.

medRxiv : the preprint server for health sciences·2026
Same author

A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice.

Diabetes, obesity & metabolism·2025
Same author

The physiological impact of an N-terminal Halo-tag on glucose-dependent insulinotropic polypeptide receptor function in mice.

Diabetes, obesity & metabolism·2025
Same author

Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation.

Molecular metabolism·2025
Same author

Dietary protein defends lean mass and maintains the metabolic benefits of glucagon receptor agonism in mice.

Molecular metabolism·2024
Same author

Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2024

Area of Science:

  • Endocrinology
  • Gastroenterology
  • Metabolic diseases

Background:

  • Gut hormones play a crucial role in regulating appetite and body weight.
  • Obesity is a leading cause of premature death globally, with accelerating prevalence.
  • Current anti-obesity therapies are limited, highlighting the need for novel approaches.

Purpose of the Study:

  • To investigate the potential of peptide YY (PYY) as an anti-obesity therapy.
  • To explore the role of gut hormones in appetite regulation and their implications for obesity treatment.

Main Methods:

  • Review of existing literature on gut hormones and their effects on food intake.
  • Analysis of hormone levels in obese versus non-obese individuals.
  • Exploration of therapeutic strategies involving hormone replacement.

Related Experiment Videos

Main Results:

  • Ghrelin stimulates appetite, while several other gut hormones, including PYY, inhibit it.
  • Obese individuals often exhibit lower levels of PYY.
  • Modulating PYY levels could impact food intake and body weight.

Conclusions:

  • Restoring reduced PYY levels in obese individuals may represent a promising therapeutic strategy.
  • Targeting gut hormone imbalances offers a potential avenue for combating the obesity pandemic.
  • Further research into PYY replacement therapy is warranted.